Replimune announced fiscal 2026 financial results and confirmed the FDA accepted its resubmission of the BLA for RP1 in combination with nivolumab for advanced melanoma with a goal date set for August 2026. This regulatory milestone, combined with strong clinical data presentations, supports the company's progress in securing approval for its oncolytic immunotherapy portfolio.